Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
Menu
Articles
Author Correction
Autoimmune Diseases
Brief Report
Cardiovascular Conditions
Commentary
Correspondence
Dermatological Diseases
Endocrine Diseases
Gastrointestinal Conditions
General Indications
Hematology
Hereditary Genetic Disorders
Infectious Diseases
Methodology and Healthcare Policy
Nephrologic/Hepatologic Conditions
Neurological Diseases
Oncology
Ophthalmology
Other Conditions
Perspective
Psychological Conditions
Respiratory Diseases
Trauma Induced Conditions
Urological/Gynecological Diseases
All
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers
search
Sorry, something went wrong. Please try your search again.
×
Use advanced search instead (articles only)
Articles
Blog posts
RSS Feed
Enter the URL below into your favorite RSS reader.
https://jheor.org/feed
×
Neurological Diseases
Vol. 1, Issue 1, 2013
May 24, 2013 EDT
The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication
Christian Frois
,
Thomas O’Connell
,
Jacqueline Pesa
,
John Fastenau
,
prior authorization
access
formulary
preferred drug list (pdl)
medicaid
schizophrenia
antipsychotic
Copyright Logo
ccby-4.0
•
https://doi.org/10.36469/9853
Photo by
freestocks.org
on
Unsplash
JHEOR
1.
Frois C, O’Connell T, Pesa J, Fastenau J. The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication.
JHEOR
. 2013;1(1):54-61.
doi:10.36469/9853
Save article as...
▾
PDF
XML
Citation (BibTeX)
View more stats